Joint (NASDAQ:JYNT) Issues Quarterly Earnings Results, Meets Expectations

Joint (NASDAQ:JYNT) posted its quarterly earnings data on Thursday. The company reported $0.05 EPS for the quarter, hitting analysts’ consensus estimates of $0.05, FiscalAI reports. Joint had a return on equity of 11.70% and a net margin of 6.49%.The company had revenue of $15.18 million for the quarter, compared to the consensus estimate of $14.57 million.

Here are the key takeaways from Joint’s conference call:

• Profitability and cash flow improved sharply: Q2 revenue rose 14% to $15.2 million, Adjusted EBITDA from continuing operations increased to $1.5 million from $88,000, and free cash flow grew $1.6 million to $1.9 million.
• Refranchising is nearing completion, with clinic ownership transfers and management service agreements progressing across the three sale bundles. Once finalized, The Joint expects to have only three remaining company-owned or managed clinics, supporting a more capital-light model.
• Patient retention reached its best level in more than five years following the rollout of flexible membership options, while active-member trends improved sequentially. Management also reported no meaningful patient pushback to price increases implemented at more than 500 clinics.
• System-wide sales declined 3.7% year over year and Q2 comparable sales were negative 2.8%, although management said July and second-half trends were improving.
• The company reduced its 2026 new-clinic opening outlook to 22–26 from 30–35, and expects year-end clinic count to be below 2025 levels as closures and portfolio optimization offset new openings. Full-year guidance was otherwise reiterated, including $12.5 million–$13.5 million of consolidated Adjusted EBITDA.

Joint Stock Performance

Shares of Joint stock traded up $0.11 on Friday, reaching $8.33. The stock had a trading volume of 104,765 shares, compared to its average volume of 60,308. The business’s 50-day moving average price is $8.76 and its two-hundred day moving average price is $8.87. The stock has a market cap of $118.79 million, a P/E ratio of 30.85 and a beta of 1.10. Joint has a fifty-two week low of $7.50 and a fifty-two week high of $11.26.

Insider Buying and Selling

In other news, major shareholder Charles E. Jobson bought 127,676 shares of the company’s stock in a transaction that occurred on Tuesday, May 12th. The shares were purchased at an average price of $8.57 per share, for a total transaction of $1,094,183.32. Following the acquisition, the insider directly owned 1,773,479 shares of the company’s stock, valued at $15,198,715.03. The trade was a 7.76% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 30.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Joint

Hedge funds have recently bought and sold shares of the company. BNP Paribas Financial Markets increased its stake in shares of Joint by 104.7% in the third quarter. BNP Paribas Financial Markets now owns 2,935 shares of the company’s stock worth $28,000 after purchasing an additional 1,501 shares during the period. JPMorgan Chase & Co. lifted its position in shares of Joint by 32.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 7,412 shares of the company’s stock worth $86,000 after purchasing an additional 1,810 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Joint by 25.9% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 8,244 shares of the company’s stock valued at $95,000 after purchasing an additional 1,698 shares during the period. XTX Topco Ltd bought a new stake in Joint during the 4th quarter valued at approximately $124,000. Finally, Wells Fargo & Company MN grew its holdings in Joint by 78.0% in the 4th quarter. Wells Fargo & Company MN now owns 15,476 shares of the company’s stock valued at $135,000 after buying an additional 6,784 shares during the last quarter. 76.88% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on JYNT shares. Zacks Research cut shares of Joint from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. Wall Street Zen upgraded shares of Joint from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Finally, Weiss Ratings raised Joint from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, June 12th. Three analysts have rated the stock with a Hold rating, Based on data from MarketBeat, Joint has a consensus rating of “Hold”.

About Joint

The Joint Chiropractic, Inc, doing business as Joint (NASDAQ: JYNT), is a franchisor and operator of outpatient chiropractic clinics in the United States. Under its flagship The Joint Chiropractic brand, the company offers membership-based, cash-focused spinal adjustment services designed to promote accessible, routine care for neck and back discomfort. By removing insurance requirements and offering walk-in visits, Joint aims to streamline the patient experience and reduce cost barriers to ongoing chiropractic treatment.

Joint’s growth strategy centers on partnering with franchisees to expand its network of clinics.